[go: up one dir, main page]

EA201790160A1 - Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d - Google Patents

Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d

Info

Publication number
EA201790160A1
EA201790160A1 EA201790160A EA201790160A EA201790160A1 EA 201790160 A1 EA201790160 A1 EA 201790160A1 EA 201790160 A EA201790160 A EA 201790160A EA 201790160 A EA201790160 A EA 201790160A EA 201790160 A1 EA201790160 A1 EA 201790160A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepatitis
caused
virus
methods
viruses
Prior art date
Application number
EA201790160A
Other languages
English (en)
Other versions
EA036745B1 (ru
Inventor
Эндрю Вайан
Original Assignee
Репликор Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790160(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Репликор Инк. filed Critical Репликор Инк.
Publication of EA201790160A1 publication Critical patent/EA201790160A1/ru
Publication of EA036745B1 publication Critical patent/EA036745B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Раскрыт способ лечения инфекции, вызванной вирусом гепатита В, или коинфекции, вызванной вирусом гепатита В/вирусом гепатита дельта, способ, включающий введение субъекту, нуждающемуся в подобном лечении, первого фармацевтически приемлемого средства, которое содержит по меньшей мере один тиофосфатный полимер нуклеиновой кислоты, и второго фармацевтически приемлемого средства, которое содержит по меньшей мере один нуклеозидный/нуклеотидный аналог-ингибитор полимеразы вируса гепатита В.
EA201790160A 2014-07-10 2015-07-07 Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d EA036745B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Publications (2)

Publication Number Publication Date
EA201790160A1 true EA201790160A1 (ru) 2017-06-30
EA036745B1 EA036745B1 (ru) 2020-12-16

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790160A EA036745B1 (ru) 2014-07-10 2015-07-07 Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d

Country Status (33)

Country Link
US (1) US9603865B2 (ru)
EP (1) EP3166615B1 (ru)
JP (2) JP2017521433A (ru)
KR (2) KR20170029577A (ru)
CN (2) CN106659730A (ru)
AU (1) AU2015286199B2 (ru)
BR (1) BR112017000320B1 (ru)
CA (1) CA2954182C (ru)
CL (1) CL2017000008A1 (ru)
CU (1) CU20170001A7 (ru)
DK (1) DK3166615T3 (ru)
DO (1) DOP2017000002A (ru)
EA (1) EA036745B1 (ru)
EC (1) ECSP16097355A (ru)
ES (1) ES2963814T3 (ru)
FI (1) FI3166615T3 (ru)
HK (1) HK1231402A1 (ru)
HR (1) HRP20231400T1 (ru)
HU (1) HUE064449T2 (ru)
IL (1) IL249660B (ru)
LT (1) LT3166615T (ru)
MD (1) MD4760C8 (ru)
MX (1) MX381042B (ru)
MY (1) MY178087A (ru)
PH (1) PH12017500010B1 (ru)
PL (1) PL3166615T3 (ru)
PT (1) PT3166615T (ru)
RS (1) RS64833B1 (ru)
SG (1) SG11201700073PA (ru)
SI (1) SI3166615T1 (ru)
SM (1) SMT202300380T1 (ru)
TW (1) TWI766831B (ru)
WO (1) WO2016004525A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166976B2 (en) * 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
SG11202104636XA (en) * 2018-11-08 2021-06-29 Aligos Therapeutics Inc S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN113637030A (zh) * 2020-05-07 2021-11-12 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦b晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
US20240336921A1 (en) 2021-07-09 2024-10-10 Glaxo Smith Kline Intellectual Property (No. 3) Limited Use of oligonucleotides for individuals with renal impairment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
CA2498777C (en) 2002-09-13 2015-01-13 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2006091798A2 (en) * 2005-02-22 2006-08-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus
HUE029521T2 (en) 2010-08-20 2017-03-28 Replicor Inc Oligonucleotide chelate complexes
ES2663009T3 (es) * 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
SMT202100319T1 (it) * 2012-05-18 2021-09-14 Replicor Inc Composizioni e metodi del complesso oligonucleotide chelato polipeptidico
SG11201501255PA (en) * 2012-08-30 2015-03-30 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
ES2963814T3 (es) 2024-04-02
JP2017521433A (ja) 2017-08-03
FI3166615T3 (fi) 2023-11-06
HK1231402A1 (zh) 2017-12-22
CN106659730A (zh) 2017-05-10
MD20170014A2 (ru) 2017-07-31
CA2954182A1 (en) 2016-01-14
MX2017000053A (es) 2017-05-01
US20160008393A1 (en) 2016-01-14
RS64833B1 (sr) 2023-12-29
US9603865B2 (en) 2017-03-28
HRP20231400T1 (hr) 2024-02-16
IL249660A0 (en) 2017-02-28
MD4760B1 (ru) 2021-07-31
MX381042B (es) 2025-03-12
JP2020143065A (ja) 2020-09-10
PH12017500010A1 (en) 2017-05-15
ECSP16097355A (es) 2017-03-31
EP3166615B1 (en) 2023-08-09
SMT202300380T1 (it) 2024-01-10
BR112017000320A2 (pt) 2017-11-07
HUE064449T2 (hu) 2024-03-28
CN113750112A (zh) 2021-12-07
EP3166615A4 (en) 2018-01-17
DK3166615T3 (da) 2023-11-13
SG11201700073PA (en) 2017-02-27
BR112017000320B1 (pt) 2023-02-07
KR20170029577A (ko) 2017-03-15
JP6922030B2 (ja) 2021-08-18
PT3166615T (pt) 2023-11-13
EA036745B1 (ru) 2020-12-16
EP3166615A1 (en) 2017-05-17
DOP2017000002A (es) 2017-03-15
CA2954182C (en) 2023-08-15
PH12017500010B1 (en) 2022-07-29
PL3166615T3 (pl) 2024-02-19
WO2016004525A1 (en) 2016-01-14
IL249660B (en) 2022-02-01
AU2015286199A1 (en) 2017-02-23
CU20170001A7 (es) 2017-04-05
NZ727583A (en) 2024-08-30
LT3166615T (lt) 2024-01-25
SI3166615T1 (sl) 2023-12-29
TW201613617A (en) 2016-04-16
KR102734495B1 (ko) 2024-11-25
TWI766831B (zh) 2022-06-11
MD4760C8 (ru) 2022-02-28
CL2017000008A1 (es) 2017-06-09
AU2015286199B2 (en) 2020-05-14
MY178087A (en) 2020-10-02
KR20230070330A (ko) 2023-05-22

Similar Documents

Publication Publication Date Title
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
PH12018500931A1 (en) Hcv polymerase inhibitors
MX377531B (es) Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón.
EA201790597A1 (ru) Способы лечения вирусных инфекций filoviridae
JOP20200092A1 (ar) تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
MX373703B (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
EA201600226A1 (ru) Способы и композиции для рнк-направленного лечения вич-инфекции
EA201990628A1 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
EA201891975A1 (ru) Тиазолидные соединения для лечения вирусных инфекций
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
HK1251010A1 (zh) 用於治療乙型肝炎病毒(hbv)感染的試劑及用途
EP3370723A4 (en) TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
EA201790778A1 (ru) Фармацевтические композиции длительного действия от гепатита с
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
MA40218A (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d
EA202191771A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ RNAi ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
EA201990021A1 (ru) Способы лечения вирусных инфекций filoviridae
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в
EA202092602A2 (ru) -d-2'-дезокси-2'--фтор-2'--c-замещенные-2-модифицированные-n6-замещенные пуриновые нуклеотиды для лечения вызванных hcv заболеваний
TH1601005264A (ru)